THE TAPE
AHR · REITs · $12.7B

American Healthcare REIT, Inc.

$58.07▲ +0.50%
Last close
Relative strength
68RS
of 99, against every stock▲ +8 on the month
Powering up
Stock-specific strength
+18.9%
six months against REITs
52-week range
−2.5%
from the high
$44.81$59.55
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +30% on a year ago
Why it is on no screen

AHR is off the screens on one check: relative strength.

A base has formed14.6 weeks, from 49.25 to 58.70.
Long enough to count14.6 weeks against 3 needed.
Shallow enough16.1% deep against 35% allowed.
Close to its pivot-1.1% from the pivot; listed down to -20%.
Relative strengthRS 68 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$57.21
-1.5% · tested 3× · last 52 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

American Healthcare REIT, Inc. is not on any of the screens right now. Its relative strength rating is 68, and it sits in REITs.

Against its industry
Stock-specific strengthAhead of its industry over all three, in an industry that is behind the S&P 500 over six months: strength the group does not share.
One month against its industry
+5.8%
Three months against its industry
+12.8%
Six months against its industry
+18.9%

Read against an equal-weighted index of REITs, which is -2.6% against the S&P 500 over six months Not aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.7B
+29.5% year on year
Operating margin
20.2%
Net margin
3.6%
Free cash flow
$421.7M
3.3% of market cap
Price to sales
4.74×
Price to earnings
130.1×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$742.1M
+10.1% QoQ · +29.5% YoY
Gross margin
—
Net income
$31.2M
Positive
Free cash flow
$166.9M
Cash generating

What the numbers say

  • Good: Revenue +29.5% year over year, +10.1% on the quarter
  • Good: Profitable: net income $31M, operating margin 22.2%
  • Good: Cash generating: operating cash flow $167M, free cash flow $167M
  • Weak: Share count +28.2% in a year: dilution
  • Good: Net cash $223M · cash $223M
Revenue by quarter
Free cash flow
Net income
shares +28.2% in a year · net cash $222.8M
Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is funding the growth from operations: share count +28.2% in a year: dilution.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-14
3 lower closes in a leading group, 50d held, at 57.78
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
Tightening after a sharp runTape · 2026-11-14
range halved after a +16% thrust, at 57.78
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Red flag in a filingFiling · 2026-11-07
material weakness
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-07
above 20d & 50d on 1.9x volume at 57.91
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Reported resultsFiling · 2026-11-06
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-04
reports 2026-11-05 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-28
below 20d & 50d on 2.2x volume at 51.06
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Unusual volumeTape · 2026-09-19
5.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
6
$1,822,663 total

Sold: ESTES SCOTT A, Foster Mark E., PEAY BRIAN.

Not counted above: 13 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-10 ESTES SCOTT A · Directorsell2,500$148,300
2026-09-25 Foster Mark E. · EVP, GC & Secretarysell1,500$78,090
2026-09-01 Foster Mark E. · EVP, GC & Secretarysell2,000$110,780
2026-07-21 Prosky Danny · Directorwithheld for tax59,945$3,396,484
2026-07-21 Prosky Danny · Directoroption exercise30,886
2026-07-21 Prosky Danny · Directorwithheld for tax16,663$944,126
2026-07-21 Prosky Danny · Directoroption exercise20,912
2026-07-21 Prosky Danny · Directorwithheld for tax11,283$639,295

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy6
Buy10
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
American Healthcare REIT, Inc. (AHR) — The Tape